• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Elephant in the Room: Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors.

作者信息

Jackevicius Cynthia A

机构信息

From the Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA; Institute for Clinical Evaluative Sciences, Toronto, Canada; Veterans Affairs Greater Los Angeles Healthcare System, CA; Institute of Health Policy, Management and Evaluation, Faculty of Medicine, University of Toronto, Canada); and University Health Network, Toronto, Canada.

出版信息

Circ Cardiovasc Qual Outcomes. 2018 Jan;11(1):e004425. doi: 10.1161/CIRCOUTCOMES.117.004425.

DOI:10.1161/CIRCOUTCOMES.117.004425
PMID:29326147
Abstract
摘要

相似文献

1
Elephant in the Room: Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors.
Circ Cardiovasc Qual Outcomes. 2018 Jan;11(1):e004425. doi: 10.1161/CIRCOUTCOMES.117.004425.
2
Unpacking and Understanding the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Apolipoprotein B Metabolism.解析并理解前蛋白转化酶枯草杆菌蛋白酶/克新蛋白酶9型抑制剂对载脂蛋白B代谢的影响
Circulation. 2017 Jan 24;135(4):363-365. doi: 10.1161/CIRCULATIONAHA.116.025897.
3
Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels: Another Piece of the Puzzle.前蛋白转化酶枯草溶菌素9型（PCSK9）血浆水平的遗传调控：谜题的又一块拼图。
Circ Genom Precis Med. 2018 May;11(5):e002165. doi: 10.1161/CIRCGEN.118.002165.
4
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke: PheWAS, TreWAS, and More.前蛋白转化酶枯草溶菌素/克新9（PCSK9）状态与缺血性中风的预防：全表型组关联研究、全转录组关联研究及其他
Circ Genom Precis Med. 2018 Jul;11(7):e002247. doi: 10.1161/CIRCGEN.118.002247.
5
A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience.前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂预先授权批准的简化途径：脂质门诊经验
J Clin Lipidol. 2017 May-Jun;11(3):596-599. doi: 10.1016/j.jacl.2017.02.015. Epub 2017 Mar 9.
6
[Gene mutations of proprotein convertase subtilisin/kexin type 9 and low density lipoprotein-cholesterol].[前蛋白转化酶枯草溶菌素/kexin 9型基因突变与低密度脂蛋白胆固醇]
Zhonghua Xin Xue Guan Bing Za Zhi. 2017 May 24;45(5):444-446. doi: 10.3760/cma.j.issn.0253-3758.2017.05.018.
7
Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367.关于德卡瓦略等人的评论。前蛋白转化酶枯草杆菌蛋白酶/克新9型（PCSK9）抑制剂与2型糖尿病发病：一项超过96000人年的系统评价和荟萃分析。《糖尿病护理》2018年；41：364 - 367。
Diabetes Care. 2018 Apr;41(4):e69. doi: 10.2337/dc17-2563.
8
Response to Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367.对关于德卡瓦略等人的评论的回应。前蛋白转化酶枯草杆菌蛋白酶/克新9型（PCSK9）抑制剂与2型糖尿病发病：一项超过96000人年的系统评价和荟萃分析。《糖尿病护理》2018年；41:364 - 367。
Diabetes Care. 2018 Apr;41(4):e70-e71. doi: 10.2337/dci17-0069.
9
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor on Oxidized Lipoprotein Levels: A Case Report.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂对氧化型脂蛋白水平的影响：一例报告
J Appl Lab Med. 2020 Sep 1;5(5):1124-1126. doi: 10.1093/jalm/jfaa052.
10
Lipid-Lowering Therapy With Monoclonal Antibodies to Proprotein Convertase Subtilisin-Kexin Type 9　- Lessons From Recent Clinical Trials.使用抗前蛋白转化酶枯草溶菌素9型单克隆抗体的降脂治疗——近期临床试验的经验教训
Circ J. 2017 Sep 25;81(10):1386-1387. doi: 10.1253/circj.CJ-17-0511. Epub 2017 Jun 3.

引用本文的文献

1
Just Price for PCSK9 Inhibitors: No less, No More.PCSK9 抑制剂的合理价格：不多不少。
J Am Heart Assoc. 2018 Nov 6;7(21):e010884. doi: 10.1161/JAHA.118.010884.